89bio, Inc. / Fundamentals

    Income statement

    Net revenue
    €18.12K
    Cost of goods sold
    €6.90K
    Gross profit
    €11.22K
    SG&A expenses
    €38.52M
    R&D expenses
    €363.37M
    EBITDA
    -€392.79M
    D&A
    -€3.00M
    EBIT
    -€401.90M
    Interest expenses
    €2.95M
    EBT
    -€387.38M
    Tax expenses
    €929.49K
    Net income
    -€388.54M

    Cash flow statement

    Net deferred tax
    €0.00
    Non-cash items
    -€11.51M
    Changes in working capital
    -€1.57M
    Operating cash flow
    -€378.96M
    Capex
    €62.14K
    Other investing cash flow
    €12.08M
    Net investing cash flow
    -€89.13M
    Total cash dividends paid
    €0.00
    Issuance of common stock
    €368.90M
    Debt repayment
    €8.07M
    Other financing cash flow
    €252.11M
    Net financing cash flow
    €396.33M
    Foreign exchange effects
    €0.00
    Net change in cash
    -€71.75M
    Cash at end of period
    €111.40M
    Free cash flow
    -€378.90M

    Balance sheet

    Cash and cash equivalents
    €111.40M
    Cash and short-term investments
    €484.30M
    Total receivables
    €0.00
    Inventory
    €0.00
    Other current assets
    €34.83M
    Total current assets
    €519.13M
    Property, plant & equipment
    €1.15M
    Goodwill
    €0.00
    Intangible assets
    €0.00
    Long-term investments
    €0.00
    Other non-current assets
    €545.44K
    Total non-current assets
    €1.70M
    Total assets
    €520.83M
    Accounts payable
    €12.65M
    Short-term debt
    €676.62K
    Other current liabilities
    €20.86M
    Total current liabilities
    €34.19M
    Long-term debt
    €586.00K
    Deferred tax liabilities
    €0.00
    Other non-current liabilities
    €35.78M
    Total non-current liabilities
    €36.37M
    Total liabilities
    €70.55M
    Common stock
    €127.73K
    Retained earnings
    -€869.33M
    Other equity
    €105.29K
    Total equity
    €450.27M
    Total liabilities and shareholders' equity
    €520.83M

    Company information

    Market capitalization
    €1.23B
    Employees
    93
    Enterprise Value
    €1.15B

    Company ratios

    Gross margin
    61.9% Much better than peer group: -667,933.7%
    EBITDA margin
    -2,167,281.0% Much worse than peer group: -10,930.6%
    EBIT margin
    -2,217,504.8% Much worse than peer group: -11,493.3%
    EBT margin
    -2,137,404.8% Much worse than peer group: -11,860.7%
    Net margin
    -2,143,838.1% Much worse than peer group: -11,237.6%
    ROE
    -86.3% Much worse than peer group: -41.9%
    ROA
    -74.6% Better than peer group: -90.9%
    Asset turnover
    0.0% Worse than peer group: 13.3%
    FCF margin
    -2,091,300.0% Much worse than peer group: -8,558.2%
    FCF yield
    -30.9%
    Efficiency ratio
    2,167,381.0%
    Net sales per employee
    €194.88
    Net income per employee
    -€4.18M

    Notifications